Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:HRMY NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.48+0.0%$31.31$19.05▼$32.56$3.85B0.741.90 million shs3.38 million shsHRMYHarmony Biosciences$35.54-3.5%$33.27$25.52▼$40.87$2.13B0.94719,259 shs648,137 shsNVAXNovavax$8.91-4.5%$9.39$6.20▼$11.97$1.53B2.434.09 million shs3.85 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.03%-0.06%+0.38%+20.20%+44.34%HRMYHarmony Biosciences-3.53%-3.97%+3.13%+21.34%+4.53%NVAXNovavax-4.50%-4.71%+0.34%+6.20%+30.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.48+0.0%$31.31$19.05▼$32.56$3.85B0.741.90 million shs3.38 million shsHRMYHarmony Biosciences$35.54-3.5%$33.27$25.52▼$40.87$2.13B0.94719,259 shs648,137 shsNVAXNovavax$8.91-4.5%$9.39$6.20▼$11.97$1.53B2.434.09 million shs3.85 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.03%-0.06%+0.38%+20.20%+44.34%HRMYHarmony Biosciences-3.53%-3.97%+3.13%+21.34%+4.53%NVAXNovavax-4.50%-4.71%+0.34%+6.20%+30.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.001.65% UpsideHRMYHarmony Biosciences 2.30Hold$42.5019.58% UpsideNVAXNovavax 2.40Hold$13.0045.90% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, HRMY, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026NVAXNovavax Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/30/2026HRMYHarmony Biosciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$30.00 ➝ $36.006/24/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/11/2026NVAXNovavax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/3/2026CPRXCatalyst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/28/2026CPRXCatalyst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/22/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026CPRXCatalyst Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/8/2026HRMYHarmony Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$25.00 ➝ $29.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$588.99M6.54$2.92 per share10.77$7.76 per share4.06HRMYHarmony Biosciences$868.45M2.37$3.07 per share11.59$15.11 per share2.35NVAXNovavax$1.12B1.30$3.35 per share2.66($0.79) per share-11.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.7418.0910.220.9637.08%35.76%31.31%8/5/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4814.339.280.3516.20%17.19%11.99%8/4/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)Latest CPRX, HRMY, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026CPRXCatalyst Pharmaceuticals$0.48N/AN/AN/A$155.79 millionN/A8/5/2026Q2 2026NVAXNovavax-$0.3961N/AN/AN/A$52.06 millionN/A8/4/2026Q2 2026HRMYHarmony Biosciences$0.87N/AN/AN/A$242.14 millionN/A5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A7.106.84HRMYHarmony Biosciences0.153.583.56NVAXNovavaxN/A2.482.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%HRMYHarmony Biosciences86.23%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%HRMYHarmony Biosciences11.00%NVAXNovavax1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.42 million109.69 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableNVAXNovavax1,990164.44 million161.81 millionOptionableCPRX, HRMY, and NVAX HeadlinesRecent News About These CompaniesNovavax Target of Unusually Large Options Trading (NASDAQ:NVAX)July 10, 2026 | marketbeat.comFBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study DataJuly 10, 2026 | finance.yahoo.comNovavax (NVAX) Dropped From Major Russell Growth Indices And Why It MattersJuly 10, 2026 | finance.yahoo.comNovavax (NVAX) Leaves Russell Growth Indexes, Is The 32% Undervaluation Case Convincing?July 10, 2026 | finance.yahoo.comTVRD Stock Rallies 149% So Far This Week: Here's What You Should KnowJuly 9, 2026 | finance.yahoo.comZacks Research Predicts Novavax's Q1 Earnings (NASDAQ:NVAX)July 9, 2026 | marketbeat.comNovavax Inc. stock outperforms competitors despite losses on the dayJuly 8, 2026 | marketwatch.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsJuly 8, 2026 | finance.yahoo.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsJuly 8, 2026 | zacks.comBasilea Pharmaceutica (OTCMKTS:BPMUF) and Novavax (NASDAQ:NVAX) Head-To-Head ComparisonJuly 8, 2026 | americanbankingnews.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItJuly 7, 2026 | finance.yahoo.comAtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression StudyJuly 7, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItJuly 7, 2026 | zacks.comNovavax Inc. stock underperforms Thursday when compared to competitors despite daily gainsJuly 3, 2026 | marketwatch.comNovavax (NVAX) Stock Moves 1.36%: What You Should KnowJuly 3, 2026 | finance.yahoo.com1 Healthcare Stock with Impressive Fundamentals and 2 We Turn DownJuly 2, 2026 | finance.yahoo.comNovavax Inc. stock underperforms Friday when compared to competitors despite daily gainsJune 26, 2026 | marketwatch.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsJune 24, 2026 | finance.yahoo.comNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsJune 24, 2026 | zacks.comNovavax faces renewed attack by Shah Capital after AGMJune 24, 2026 | msn.comShah Capital Responds to Significant Shareholder Dissent at Novavax AGMJune 24, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, HRMY, and NVAX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.48 +0.01 (+0.03%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$31.47 -0.01 (-0.03%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Harmony Biosciences NASDAQ:HRMY$35.54 -1.30 (-3.53%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$35.53 -0.01 (-0.03%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Novavax NASDAQ:NVAX$8.91 -0.42 (-4.50%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$8.96 +0.04 (+0.51%) As of 06:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
